A male patient in his 20s presented at our clinic with pain caused by bone metastases of the primitive neuroectodermal tumor, and Sr-89 was administrated to palliate the pain. After receiving the injection, the patient complained of a slight burning pain at the catheterized area. Slight reddening and small circular swelling (diameter, 0.5 cm) were observed at the catheterized area. Sr-89 extravasation was suspected. To estimate the amount of subcutaneous Sr-89 leakage, bremsstrahlung imaging was immediately performed. We speculated that the skin-absorbed dose from subcutaneous infiltration of Sr-89 was 1.78 Gy. The mildest clinical sign of local radiation injury was erythema. The received dose was higher than 3 Gy, and the time of onset was from 2 to 3 weeks. In our patient, local radiation injuries (LRIs) did not occur. Though requiring further verification, subsequent bremsstrahlung imaging and estimation of the skin-absorbed dose from the subcutaneous infiltration of Sr-89 are useful in confirming Sr-89 extravasation and in the decision making for the choice of treatment strategies for LRIs caused by Sr-89 extravasation.
Introduction
Reports on cases of local radiation injuries (LRIs) caused by the extravasation of therapeutic radionuclides are rare. In a PubMed search, a report on Y-90 extravasation was found (1) , but none on Sr-89 extravasation. With the increasing use of therapeutic radionuclides, a corresponding increase in LRI cases resulting from possible extravasation is expected. When the extravasation of radionuclide is suspected at injection, extravasation should be confirmed and the radionuclide dose absorbed by the skin should be measured (2, 3) . Here, we present a case of Sr-89 extravasation, for which we used bremsstr the amo predict t predicted correctly that LRIs would not occur in our patient.
Case Rep

Discussion
Since the first report (3) of LRI caused by subcutaneous Tl-201 extravasation in 2001, the methods of measuring skin-absorbed dose from the subcutaneous Sr-89 infiltration have been evaluated and improved, (3, 7, 10) leading to the development of safety manuals for the management of therapeutic radionuclide extravasation. (2, 11) Williams et al (1) indicated that morbidity of LRIs may be reduced by identifying extravasation at the intravenous injection site of the radionuclide and by providing early treatment immediately after confirming the extravasation.
Safety guidelines for suspected Sr-89 extravasations, have the following recommendations (1, 2, 10, 11):
1) Mark the region of extravasation (if possible, take a photograph of the region). 2) Perform warming to promote vasodilatation and possible removal and dilution of the extravasated Sr-89 and to relieve pain. 3) Consider administration of steroids. 4) As soon as possible, monitor the remaining fraction of the skin-absorbed dose from the subcutaneous Sr-89 infiltration by bremsstrahlung imaging. 5) Consult a dermatologist. In the manual, performing bremsstrahlung imaging was not mentioned. Skin-absorbed dose of Sr-89 from subcutaneous leakage was calculated in accordance with the method of Yamaguchi et al (3, 7, 8) as described by Kobayashi et al (3). Yamaguchi et al assumed that the amount of radionuclide extravasation is approximately onethird of the whole quantity. In the manual (2, 3) the average ratio of Sr-89 extravasations was assumed to be 30%. However, the ratio varies according to each case. We actually measured the ratio by bremsstrahlung images. Yamaguchi et al supposed that the contaminated area of the Sr-89 from subcutaneous leakage was 10 cm 2 . According to the inspection, instead of 10 cm 2 , we supposed that the contaminated area was the small circular swelling (diameter, 0.5 cm) in the catheterized area in order not to underestimate the skin-absorbed dose from the subcutaneous Sr-89 infiltration. Other calculating methods of skin absorbed doses due to subcutaneous leakage of radioactive pharmaceuticals were proposed by Minsky et al (12) , Shapiro et al (13) and ICRU Report 56 (8) and so on. Kobayashi et al illustrated that the calculating method by yamaguchi et al was the most suitable for the supposition of the skin absorbed doses.
In this case, the square ROI (ROI 1) and the background ROI (ROI 3) were determined instead of the ROI surrounding the whole body uptake, because it was difficult to determine along the counter of the whole body uptake correctly and in order to remove the influences from the environment background and scatter radiations. As a result, overestimation of uptake and absorbed dose may be seen. Determination of square ROI was very easy and objective. This measurement of the ratio of Sr-89 extravasation was thought to be clinically useful. More study maybe needed to accurately define ROI in these patients.
In our case, bremsstrahlung imaging was performed immediately after radionuclide injection, which had 2 benefits. First, it allowed us to confirm the occurrence of extravasation. Second, it enabled us to perform quantitative measurement of the ratio of Sr-89 extravasation. The measurement was clinically useful for the treatment strategy and the prediction of prognosis of this patient. The bremsstrahlung imaging technique that we used in the present case requires further technical evaluation. Oda et al (14) indicated that setting the energy window at 75 keV (window width of 50%) with the use of a medium energy low penetration collimator (MELP) collimator is optimal for imaging. Next time, the pulse-height analyzers may be set at 75 keV photo-peak with a window width of 50% with MELP collimator.
Conclusion
When subcutaneous extravasation is suspected after injection of Sr-89, we would recommend performing bremsstrahlung imaging immediately and starting supportive treatment early.
